Obesity and endocrine disorders in women taking valproate for epilepsy
- 1 May 1996
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 39 (5), 579-584
- https://doi.org/10.1002/ana.410390506
Abstract
We recently reported the frequent occurrence of polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy, especially when the medication was started before the age of 20 years. In the present study we evaluated the association of obesity and hyperinsulinemia with valproate‐related polycystic ovaries and hyperandrogenism in women with epilepsy. Sixty‐five women participated in the study. Twenty‐two received valproate monotherapy and 43 received carbamazepine monotherapy. In addition to clinical examination, vaginal ultrasonography was performed to determine ovarian size, and the concentrations of serum sex hormones, insulin, insulin‐like growth factor I, and the insulin‐like growth factor‐binding proteins 1 and 3 (IGFBP‐1 and IGFBP‐3) were measured. Fifty‐nine percent of the women on valproate were obese, and in a retrospective analysis an indisputable weight gain (mean, 21 kg, range, 8 ‐49 kg) was found in 50% of the women taking valproate. Fourteen (64%) of the women on valproate had polycystic ovaries, hyperandrogenism, or both. These women were obese, and in addition to elevated serum androgen levels, they had high concentrations of fasting serum insulin and low levels of serum insulin‐like growth factor‐binding protein 1. Valproate therapy for epilepsy is associated with weight gain during treatment in approximately 50% of women patients. The weight gain can be progressive, and is associated with hyperinsulinemia and low serum levels of insulin‐like growth factor‐binding protein 1, which may lead to hyperandrogenism and polycystic ovaries.Keywords
This publication has 22 references indexed in Scilit:
- Polycystic Ovary SyndromeNew England Journal of Medicine, 1995
- Polycystic Ovaries and Hyperandrogenism in Women Taking Valproate for EpilepsyNew England Journal of Medicine, 1993
- The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women*Clinical Endocrinology, 1993
- Metabolic changes during treatment with valproate in humans: Implication for untoward weight gainMetabolism, 1992
- The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent developments on the structure, molecular biology and functionThe Journal of Steroid Biochemistry and Molecular Biology, 1991
- Characterization of Obese Women with Reduced Sex Hormone-Binding Globulin ConcentrationsHormone and Metabolic Research, 1990
- EFFECT OF INSULIN-LIKE GROWTH FACTOR-TYPE I (IGF-I) AND INSULIN ON THE SECRETION OF SEX HORMONE BINDING GLOBULIN AND IGF-I BINDING PROTEIN (IBP-I) BY HUMAN HEPATOMA CELLSJournal of Endocrinology, 1990
- Decreased 34K insulin-like growth factor binding protein in polycystic ovarian diseaseFertility and Sterility, 1989
- Weight gain during treatment with valproateActa Neurologica Scandinavica, 1984
- Effects of sodium valproate in 100 children with special reference to weight.BMJ, 1981